AcroBiosystems社 SSTR2, a potential therapeutic target for cancer
SSTR2, a potential therapeutic target for cancer
SSTR2 (Somatostatin Receptor2) is widely expressed in solid tumors. Since it is highly expressed in neuroendocrine tumors (NETs), SSTR2 is the key target for the treatment of NETs at present.
Recent studies have shown that SSTR2 is significantly methylated in colorectal cancer and has also been implicated in tumorigenesis in gastric and breast cancers. Furthermore, the researchers found that SST binding to SSTR2 inhibited the release of cytokines from immune cells and impacted on the tumor microenvironment (TME).
The Expression of SSTR2 in 20 cancers from the Human Protein Atlas
SSTR2 is a member of the G protein-coupled receptor (GPCR) family and a seven-pass transmembrane protein with the N-terminal extracellular and the C-terminal intracellular. ACROBiosystems has successfully developed HEK293 expressed full-length SSTR2-VLP protein (Met 1-Ile 369) via "FLAG" to support drugs and therapies R&D targeting SSTR2.
The Structure of SSTR2
◆Full-length SSTR2 6-VLP Protein (Cat. No. SS2-H5216)
High bioactivity verified by ELISA
Immobilized Human SSTR2 Full Length Protein-VLP (Cat. No. SS2-H5216) at 10 μg/mL (100 μL/well) can bind Anti SSTR2 Monoclonal Antibody, Mouse IgG with a linear range of 0.005-0.625 μg/mL (QC tested).
>>>Learn more about “FLAG”: full-length multi-pass transmembrane proteins and technology platforms
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。